163 related articles for article (PubMed ID: 29394170)
1. Harnessing the PD-1 Pathway in Myelodysplastic Syndrome.
Mukherjee S; Ibrahimi S; Aljumaily R; Cherry M
Am J Ther; 2018; 25(6):e711-e712. PubMed ID: 29394170
[No Abstract] [Full Text] [Related]
2. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two?
Ohyashiki K; Yokoyama K; Kimura Y; Ohyashiki JH; Ito T; Kuratsuji T; Komatsumoto S; Nara M; Toyama K
Leukemia; 1993 Feb; 7(2):338-40. PubMed ID: 8426488
[TBL] [Abstract][Full Text] [Related]
3. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
Front Immunol; 2018; 9():1769. PubMed ID: 30108590
[TBL] [Abstract][Full Text] [Related]
4. Classification of the myelodysplastic syndromes.
Bennett JM
Clin Haematol; 1986 Nov; 15(4):909-23. PubMed ID: 3471370
[No Abstract] [Full Text] [Related]
5. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report.
Jiang R; Xu L; Huang Y; Fang C; Guo H; Li S; Wu J; Du Z
Pancreas; 2018 Sep; 47(8):e53-e54. PubMed ID: 30113432
[No Abstract] [Full Text] [Related]
7. Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma.
Damlaj M; Alzayed M; Alahmari B; Alhejazi A; Alaskar A; Alzahrani M
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):e559-e563. PubMed ID: 31377210
[No Abstract] [Full Text] [Related]
8. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
Roth P; Valavanis A; Weller M
Neuro Oncol; 2017 Mar; 19(3):454-456. PubMed ID: 28039369
[No Abstract] [Full Text] [Related]
9. Exceptional response to anti-PD-1 treatment in a patient with metastatic cutaneous hidradenocarcinoma.
Obermann H; Schmidle P; Steimle-Grauer SA; Pfarr N; Posch C
Eur J Cancer; 2021 Mar; 145():143-145. PubMed ID: 33465705
[No Abstract] [Full Text] [Related]
10. Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor.
El Mouallem N; Smith SC; Paul AK
J Oncol Pract; 2018 Aug; 14(8):511-513. PubMed ID: 29920137
[No Abstract] [Full Text] [Related]
11. Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis.
Creelan BC; Ahmad MU; Kaszuba FJ; Khalil FK; Welsh AW; Ozdemirli M; Grant NN; Subramaniam DS
Oncologist; 2019 Jun; 24(6):829-835. PubMed ID: 30842242
[TBL] [Abstract][Full Text] [Related]
12. A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy.
Lee SY; Kim MH; Jang M; Park Y; Cho BC
Eur J Cancer; 2018 Nov; 104():104-107. PubMed ID: 30342309
[No Abstract] [Full Text] [Related]
13. [Clinical picture and diagnosis of refractory anemia with an excess of blasts and with bone marrow hypoplasia].
Gladysh VV; Turbina NS; Mikhaĭlova EA; Ustinova EN; Pylaeva NN
Gematol Transfuziol; 1989 Jul; 34(7):6-10. PubMed ID: 2792720
[TBL] [Abstract][Full Text] [Related]
14. PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report.
Goldman JW; Abdalla B; Mendenhall MA; Sisk A; Hunt J; Danovitch GM; Lum EL
BMC Nephrol; 2018 Aug; 19(1):210. PubMed ID: 30126374
[TBL] [Abstract][Full Text] [Related]
15. Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy.
Panariello L; Fattore D; Annunziata MC; Piantedosi F; Gilli M; Fabbrocini G
Eur J Cancer; 2018 Nov; 103():284-286. PubMed ID: 30268391
[No Abstract] [Full Text] [Related]
16. Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
Komatsu T; Nakamura K; Kawase A
J Thorac Oncol; 2017 Sep; 12(9):e143-e144. PubMed ID: 28838715
[No Abstract] [Full Text] [Related]
17. Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know.
Filetti M; Giusti R; Di Napoli A; Iacono D; Marchetti P
Tumori; 2019 Dec; 105(6):NP48-NP51. PubMed ID: 31221037
[TBL] [Abstract][Full Text] [Related]
18. PDL-1/PD1 inhibitors: antibody or antinobody?
Aoun F; Rassy EE; Assi T; Kattan J
Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
[No Abstract] [Full Text] [Related]
19. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
[No Abstract] [Full Text] [Related]
20. A specific cutaneous lesion revealing myelodysplastic syndrome.
Kajisawa C; Matsui C; Morohashi M
Eur J Dermatol; 1998; 8(7):517-8. PubMed ID: 9854168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
